Skip to content

This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.

Order Voraxaze

This is a promotional website intended for licensed healthcare professionals
or prescribed patients in the United Kingdom or Republic of Ireland.
Please select one of the following:

I am a patient

Continue

I am a Healthcare Professional

Outside of the UK

United States (EN) Germany (DE)

I am a Healthcare Professional
In the UK

UK-VRX-2600029 Date of Last Revision: April 2026

Steer
with
Guidance

 Helping physicians navigate
HDMTX* treatment pathways 

FOR THE MANAGEMENT OF [HIGH DOSE] MTX TOXICITY
AUTHORISED UNDER EXCEPTIONAL CIRCUMSTANCES

Voraxaze® is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination.1
Delayed methotrexate (MTX) elimination can be an oncologic emergency2
Group 15

Why Stock Voraxaze

Voraxaze lowers plasma MTX by a median reduction of >98% in 15 minutes.1

View Efficacy
Frame 1000011145

High-Dose Methotrexate (HDMTX) Toxicity and Acute Kidney Injury

Keep Voraxaze top-of-mind when treating with HDMTX

Learn about HDMXT Toxicity
Group 16

Identify and TreatDelayed MTX Clearance Early

Consensus Guidelines recommend early use of Voraxaze.2

View Guidelines

Latest Updates

View All
thumb_4 copy

Delayed MTX Elimination in Practice: Recognise Risk, Act Early, Protect Outcomes

Watch this expert-led webinar to understand why early kidney function monitoring and prompt action are critical in managing HDMTX toxicity. Gain practical guidance to support clinical decision-making and improve patient outcomes.

UK-VRX-2600037 Date of Preparation: April 2026

WATCH NOW
thumb_3-1

AKI in Cancer Patients Receiving HDMTX: Why Early Recognition Matters – BOPA 2025 Symposium

Watch this recording to hear from a nephrologist, haematologist & pharmacist sharing practical insights on delayed methotrexate elimination, early AKI recognition and protecting renal outcomes in patients receiving HDMTX.

UK-VRX-2500082 Date of Preparation: April 2026

WATCH NOW
image 20

Managing delayed MTX elimination with glucarpidase in adult patients with lyphoma

Watch Anish Tailor, Lead Haematology Pharmacist from UCLH, discuss his approach to managing delayed MTX elimination with glucarpidase in adult patients with lymphoma.

UK-VRX-2500020 Date of Last Revision: February 2025

WATCH NOW

References

*High Dose Methotrexate.

  1. Summary of Product Characteristics (SmPC), Voraxaze®.
  2. Ramsey LB, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2018;23(1):52-61.

HOW TO ORDER VORAXAZE:

Order Voraxaze via Oxford Pharmacy Store (OPS)

 

9am-5pm Mon – Fri (Exc. Bank Holidays)

Call: 01865 904141 or email: ops.orders@oxfordhealth.nhs.uk Item Code: VOR002

OUT OF HOURS ORDERS (ONLY BETWEEN 5pm-10pm Mon – Fri, 9am-5pm Sat/Sun/BH):

Call Warneford Hospital switchboard on: 01865 901000 & ask to speak to the Oxford Pharmacy Store (OPS) on-call team.

PLEASE NOTE: OPS will aim to dispatch within 24 hours.

UK-VRX-2600030 Date of Last Revision: April 2026